Breathing Easier: Two New Oxygen Plants are Helping COVID-19 Patients in Ethiopia
It is the one substance that doctors worldwide agree is critical for any COVID-19 patient struggling with reduced lung capacity: oxygen. And in many developing nations, bottles of it can be too expensive and in achingly short supply.
But there’s good news from East Africa: People suffering from COVID-19 in Ethiopia’s Amhara region have supplemental oxygen from two new generation plants in the towns of Bahir Dar and Dessie. In an extraordinary case of uncannily good timing, the plants were commissioned last year, thanks to a collaboration between Assist International, a nonprofit that has been building schools and healthcare facilities in Africa for more than two decades, and the GE Foundation. The effort is part of Safe Surgery 2020, a partnership with ministries of health, academia, NGOs and surgical teams in low-income areas, to help get more patients the surgical care they need — quicker, safer and more affordably. The factories are capable of bottling roughly 240 canisters of supplemental oxygen per day, supplying more than 90 hospitals in the area, says Jim Stunkel, Assist International’s director of program operations, who has previously overseen the development of similar oxygen plants in Rwanda and Kenya.
Bottling oxygen may seem like a simple task, but the process is far from straightforward. The gas accounts for just 21% of the air around us. (Air’s other components include nitrogen (78%) and a smattering of other gases, including carbon dioxide.) Bottling oxygen begins with adsorption, a process that isolates the oxygen from the other gases. At very high pressures, some gases have a tendency to adhere to particular solids (a little like water vapor forming dew on blades of grass, though that process is driven by changes in humidity and temperature). Most oxygen-bottling plants, including those that Stunkel helped install in Ethiopia, rely on pressure swing adsorption, a process that pressurizes air to 80 pounds of force per square inch — about 5.4 times higher than the air we breathe — and then delivers it to the oxygen generator. Under pressure, nitrogen clings to the Zeolite particles inside the vessel, but oxygen doesn’t; in this way, the oxygen is separated from the ambient air. The isolated oxygen that flows out of the generator, which at 90% to 95% purity is suitable for medical use, is then pressurized into medical-grade steel cylinders.
Assist International has been pushing for years to build oxygen plants in Africa. Stunkel says the group was inspired by a 2015 resolution from the World Health Organization that said essential surgery should be part of universal healthcare in Africa and surgeons there needed access to more bottled oxygen. The next year, Assist International formed a partnership with the Amhara Regional Health Bureau of Ethiopia’s health ministry to build and manage the new oxygen plants.
Top and above images: Workers deliver oxygen to people suffering from COVID-19 in Ethiopia’s Amhara region. They now have supplemental oxygen thanks to two new generation plants in the towns of Bahir Dar and Dessie. Image credits: GE Foundation.
The Ethiopian plants opened in April 2019. Armed with supplemental oxygen, Stunkel says, doctors in the country were already “seeing a reduction statistically in mortality rates directly related to pneumonia and other things that can be solved just by the availability of medical oxygen.”
But the plants proved to be even more critical as COVID-19 spread around the world and patients suffering from the disease began to show up in Ethiopian hospitals. The oxygen the plants produced allowed healthcare workers in the region to administer supplemental doses of the gas at a time of the greatest need.
Assist International aims to transfer management of the oxygen facilities by 2023 to a local group, to be chosen by local health officials and the government. Assist International is also helping create a long-term management plan for the plants. Says Stunkel: “The concept of providing aid to countries that are in need is critical, and the sustainment plan is key to long-term success.”
-
Most popular related searches
Related news
-
U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable alternatives The U.S. Food and Drug Administration (FDA) has approved two pediatric indications for Xarelto (rivaroxaban): the...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) regarding reimbursement in France, and the CGuard EPS is being added to the list of reimbursed...
-
IFEMA MADRID will host the Congress of the European Association for Cranio Maxillo Facial Surgery in the Palacio Municipal
This biennial congress comes to Madrid as the Spanish Professor Julio Acero occupies the Presidency of the Association, and it expects to host more than 2.000 attendees from 70 countries. This edition will mean the return to the face-to-face format after the last appointment of the Congress, celebrated in Munich in 2018, and the virtual edition celebrated last summer after the impossibility of holding it in person in Paris in 2020. IFEMA MADRID continues working for the reactivation of the MICE sector in...
-
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world. Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such...
Customer comments
No comments were found for Breathing Easier: Two New Oxygen Plants are Helping COVID-19 Patients in Ethiopia. Be the first to comment!